Tanindi S, Akin R, Koseoglu V, Kurekci A E, Gokcay E, Ozcan O
Department of Pediatrics, Gulhane Military Medical Academy, Ankara, Turkey.
Thromb Res. 1996 Feb 15;81(4):471-6. doi: 10.1016/0049-3848(96)00019-9.
This study was performed to evaluate the aggregation changes in the whole blood samples of children with epilepsy receiving valproic acid. A total of 25 patients and 15 healthy volunteer adults were included in the study. Platelet aggregation study was performed in whole blood by impedance aggregometry. Platelet counts, the bleeding times, and clotting times of the patients were within normal limits. The aggregation time and maximum aggregation values revealed no significant difference except for those with 2 mu g/ml collagen (p < 0.01) between the two groups. Serum valproic acid levels of the children did not correlate with the maximum aggregation values induced by different concentrations of aggregating agents except for 20 mu M ADP (r = -0.430, p < 0.05). We concluded that the use of valproic acid does not result in thrombocytopenia and platelet dysfunction within therapeutic limits and the drug is reliable in the management of epilepsy.
本研究旨在评估接受丙戊酸治疗的癫痫患儿全血样本中的聚集变化。共有25例患者和15名健康成年志愿者纳入本研究。通过阻抗聚集法在全血中进行血小板聚集研究。患者的血小板计数、出血时间和凝血时间均在正常范围内。除了在2μg/ml胶原蛋白刺激下（p<0.01），两组之间的聚集时间和最大聚集值无显著差异。除了20μM ADP刺激下（r=-0.430，p<0.05），儿童血清丙戊酸水平与不同浓度聚集剂诱导的最大聚集值无关。我们得出结论，在治疗范围内使用丙戊酸不会导致血小板减少和血小板功能障碍，该药物在癫痫治疗中是可靠的。
